计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V302465-1mg |
1mg |
现货 ![]() |
| |
| V302465-5mg |
5mg |
现货 ![]() |
| |
| V302465-10mg |
10mg |
现货 ![]() |
| |
| V302465-25mg |
25mg |
现货 ![]() |
| |
| V302465-50mg |
50mg |
现货 ![]() |
| |
| V302465-100mg |
100mg |
现货 ![]() |
| |
| V302465-250mg |
250mg |
现货 ![]() |
|
| 英文别名 | AC-29028 | W-200739 | 1352608-82-2 | SB17272 | MFCD28348363 | N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]methyl]-2-fluoroaniline | UNII-6T4O391P5Y | 6T4O391P5Y | HY-19928 | s7530 | VACTOSERTIB [INN] | AKOS02725074 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Vactosertib (TEW-7197) |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | TGF-beta 受体 I 型抑制剂 |
| 产品介绍 |
Vactosertib (TEW-7197, EW-7197)是一种高效的,选择性的TGF-β receptor ALK4/ALK5抑制剂,IC50分别为13 nM 和 11 nM。 |
| ALogP | 3.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771399 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline |
| INCHI | InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29) |
| InChi Key | FJCDSQATIJKQKA-UHFFFAOYSA-N |
| Canonical SMILES | CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4 |
| Isomeric SMILES | CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4 |
| PubChem CID | 54766013 |
| 分子量 | 399.43 |
| 溶解性 | ≥39.9 mg/mL in DMSO; insoluble in H2O; ≥4.55 mg/mL in EtOH with ultrasonic |
|---|---|
| 熔点 | >85ºC (dec.) |
| 分子量 | 399.400 g/mol |
| XLogP3 | 3.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 399.161 Da |
| 单同位素质量Monoisotopic Mass | 399.161 Da |
| 拓扑极表面积Topological Polar Surface Area | 83.800 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 566.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC) | |
|---|---|
| Proton NMR spectrum | Conforms to Structure |
| Appearance(V302465) | Pale Yellow to Light Yellow Solid |
| 1. Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY et al.. (2014) Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.. J Med Chem, 57 (10): (4213-38). [PMID:24786585] |